AN
$73.75
+1.51
(+2.09%)
As of Oct 22, 2026, 9:32 PM EDT
Price history
Ani Pharmaceuticals Inc (ANIP) is trading up at $73.75 (+2.09%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Ani Pharmaceuticals Inc revenue & net income history (FY2016–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $128.6M | $176.8M | $201.6M | $206.5M | $208.5M | $216.1M | $316.4M | $486.8M | $614.4M | $883.4M |
| Growth (year over year) | +68.5% | +37.5% | +14.0% | +2.5% | +0.9% | +3.7% | +46.4% | +53.9% | +26.2% | +43.8% |
| Gross profit | $79.8M | $97.8M | $128.6M | $143.4M | $121.3M | $115.5M | $177.6M | $305.3M | $364.2M | $542.1M |
| Gross margin | 62.1% | 55.3% | 63.8% | 69.4% | 58.2% | 53.5% | 56.1% | 62.7% | 59.3% | 61.4% |
| Operating income | $20.1M | $28.3M | $35.4M | $16.4M | −$16.0M | −$39.8M | −$35.3M | $47.0M | $584.0K | $111.1M |
| Operating margin | 15.6% | 16.0% | 17.5% | 7.9% | −7.7% | −18.4% | −11.2% | 9.6% | 0.1% | 12.6% |
| Net income | $3.93M | −$1.08M | $15.5M | $6.09M | −$22.5M | −$42.6M | −$47.9M | $18.8M | −$18.5M | $78.3M |
| Net margin | 3.1% | −0.6% | 7.7% | 3.0% | −10.8% | −19.7% | −15.1% | 3.9% | −3.0% | 8.9% |
| EPS (diluted) | $0.34 | −$0.09 | $1.30 | $0.50 | −$1.88 | −$3.40 | −$3.05 | $0.85 | −$1.04 | $3.32 |
| Balance sheet | ||||||||||
| Cash and equivalents | $27.4M | $31.1M | $43.0M | $62.3M | $7.86M | $100.3M | $48.2M | $221.1M | $144.9M | $285.6M |
| Total assets | $322.9M | $412.1M | $430.6M | $456.8M | $461.2M | $771.6M | $760.1M | $904.4M | $1.28B | $1.44B |
| Total liabilities | $153.2M | $237.4M | $233.3M | $244.0M | $265.5M | $412.9M | $421.5M | $446.8M | $855.9M | $899.7M |
| Long-term debt | $0 | $69.9M | $67.3M | $175.8M | $172.4M | $286.5M | $285.7M | $284.8M | $309.1M | $291.8M |
| Shareholders' equity | $169.6M | $174.8M | $197.3M | $212.8M | $195.7M | $333.9M | $313.7M | $432.7M | $403.7M | $540.7M |
| Cash flow | ||||||||||
| Operating cash flow | $27.5M | $39.4M | $67.1M | $45.6M | $15.3M | $3.32M | −$31.2M | $119.0M | $64.0M | $185.2M |
| Capital expenditure | $4.57M | $10.4M | $5.74M | $6.63M | $6.13M | $2.56M | $8.88M | $8.87M | $16.2M | $13.8M |
| Free cash flow | $22.9M | $29.1M | $61.3M | $39.0M | $9.13M | $765.0K | −$40.1M | $110.1M | $47.8M | $171.4M |
| Dividends paid | — | — | — | $0 | $0 | $190.0K | $1.63M | $1.63M | $1.63M | $1.16M |
| Share buybacks | $2.50M | $0 | $0 | $1.03M | $1.52M | $890.0K | $1.96M | $4.99M | $11.0M | $12.2M |
RevenueNet incomeNet margin (right axis, %)
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $148.3M | $190.6M | $197.1M | $211.4M | $227.8M | $247.1M | $237.5M | $266.0M |
| Growth (year over year) | +12.5% | +44.8% | +43.4% | +53.1% | +53.6% | +29.6% | +20.5% | +25.9% |
| Gross profit | $85.3M | $110.3M | $124.1M | $136.8M | $134.4M | $146.8M | $143.9M | $165.9M |
| Gross margin | 57.5% | 57.9% | 62.9% | 64.7% | 59.0% | 59.4% | 60.6% | 62.4% |
| Operating income | −$20.5M | −$4.38M | $26.2M | $13.9M | $36.2M | $34.8M | $38.9M | $40.5M |
| Operating margin | −13.8% | −2.3% | 13.3% | 6.6% | 15.9% | 14.1% | 16.4% | 15.2% |
| Net income | −$24.2M | −$10.3M | $15.7M | $8.55M | $26.6M | $27.5M | $29.5M | $24.7M |
| Net margin | −16.3% | −5.4% | 8.0% | 4.0% | 11.7% | 11.1% | 12.4% | 9.3% |
| EPS (diluted) | −$1.27 | −$0.45 | $0.69 | $0.36 | $1.13 | $1.14 | $1.28 | $1.05 |
| Balance sheet | ||||||||
| Cash and equivalents | $145.0M | $144.9M | $149.8M | $217.8M | $262.6M | $285.6M | $311.2M | $360.2M |
| Total assets | $1.29B | $1.28B | $1.29B | $1.34B | $1.41B | $1.44B | $1.42B | $1.49B |
| Total liabilities | $856.6M | $855.9M | $849.0M | $881.4M | $902.3M | $899.7M | $859.7M | $896.9M |
| Long-term debt | $312.9M | $309.1M | $305.3M | $301.5M | $297.7M | $291.8M | $286.0M | $280.2M |
| Shareholders' equity | $405.9M | $403.7M | $418.6M | $436.8M | $505.8M | $540.7M | $562.3M | $597.2M |
| Cash flow | ||||||||
| Operating cash flow | $12.5M | $15.9M | $35.0M | $75.8M | $44.1M | $30.4M | $58.4M | $56.7M |
| Capital expenditure | $4.81M | $2.39M | $2.47M | $4.01M | $6.10M | $1.24M | $6.07M | $3.05M |
| Free cash flow | $7.66M | $13.5M | $32.5M | $71.8M | $38.0M | $29.1M | $52.3M | $53.6M |
| Dividends paid | $406.0K | $406.0K | $406.0K | $407.0K | $344.0K | $0 | $0 | $0 |
| Share buybacks | $680.0K | $318.0K | $10.0M | $551.0K | $1.04M | $611.0K | $19.8M | $813.0K |
From Ani Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Ani Pharmaceuticals Inc
- Headquarters
- Princeton, New Jersey From SEC filings, Oct 2026
Recent News (4)
-
ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. A…
-
Ani Pharmaceuticals general counsel Cook sells $36,795 in stock
Ani Pharmaceuticals general counsel Cook sells $36,795 in stock
-
ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that both 6-month and 24-month data from SYNCHRONICITY, its Phase 4, open-label, single-arm clinical trial of Fluocinolone…
-
ANI Pharmaceuticals at Wells Fargo conference: rare disease push gains pace
ANI Pharmaceuticals at Wells Fargo conference: rare disease push gains pace
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International